Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s
Introduction
Cancer has become a major public health problem in Europe with an estimated prevalence of about 3%, increasing to 15% at old age. Almost 50% of deaths at middle age is caused by cancer, partly resulting from lowering mortality from other causes of death. In 2002, 26% of all cancer cases in the world were diagnosed in Europe.1Fig. 1, Fig. 2 show the distribution of estimated cancer incidence and mortality for 2006; breast, colorectal, prostate and lung cancers were the most important cancer types in Europe.2
The progress against cancer is often focussed on survival of individual cancer patients. The recent paper on trends in survival of cancer across Europe up to 2002 by the EUROCARE group clearly showed that the most marked improvements occurred among patients with colorectal, breast, prostate and thyroid cancer and lymphomas, both Hodgkin’s and non-Hodgkin’s.3 Little explicit clarification was given for the observed differences between the countries. These differences may be due to variation in the baseline characteristics of the covered populations, e.g. selective areas in a country or state with large proportions of inhabitants having a high socio-economic status. Other explanations are the potentially selective incompleteness of cases at time of detection or diagnosis and during follow-up.
In the US, survival improvements were also revealed and largely determined by marked improvements in detection, thereby introducing lead-time and length bias, together with shifts in classification, subtype, and subsite resulting in pseudo-improvements of survival rates.4 To circumvent these problems, it is preferred to study simultaneously trends in cancer incidence and survival, also because both affect mortality.5, 6 Survival improvements are more often preceded by rises in incidence than followed by decreases in mortality. Table 1 summarises possible explanations for changes in incidence, survival, and mortality.
In this article we present the most recent trends in incidence, mortality, and survival over the last decade across Europe of 17 tumour sites, derived from cancer registries and mortality statistics.
Section snippets
Methods
Data of the following 17 tumour sites (and corresponding ICD-10 code) were collected: oral cavity and pharynx (C00-14), oesophagus (C15), stomach (C16), colorectal (C18-21), pancreas (C25), larynx (C32), lung (C33-34), skin melanoma (C43), female breast (C50), cervix (C53), corpus uteri (C54-55), ovary (C56), prostate (C61), testis (C62), kidney (C64-66/C68), bladder (C67), and Hodgkin’s disease (C81). They were derived from 21 European cancer registries, grouped into four regions: Northern
Results & comments
Results are presented in the accompanying tables, figures and text. Annual incidence and mortality rates per registry are provided on-line, and can be accessed at: http://www.eurocadet.org/documents/index.php?map=%2FEurocadet+publications%2FOnline+tables+trends+in+Europe+2008%2F.
Oral cavity and pharyngeal cancer (C00-14). Within Europe incidence among males in the most recent period varied substantially between 5.9 (Finland) and 32 (France) per 100,000. Mortality rates varied considerably less
General discussion
This study provides the most recent available overview of the burden of cancer in Europe. It is one of the few publications combining incidence, mortality and survival statistics of cancer. This combination is important in order to correctly interpret (trends in) cancer rates: has real progress been made or are we looking at artefacts? Observed increases in cancer incidence for example, might be real, i.e. that there are more cancer patients because of increasing risks, or they might be due to
Conclusions
The biggest achievement in cancer surveillance over the past 10 years, seems to have been the large reductions in smoking prevalence among males, hopefully soon to be followed by females.38 Lung cancer is still a very commonly diagnosed cancer, with a very poor survival, hence primary prevention by anti-smoking measures remains of utmost importance. Obesity, an upcoming problem, should be the target for prevention of oesophageal, breast, corpus uteri, cervical, prostate, and kidney cancer.74
Conflict of interest statement
None declared.
Acknowledgements
The authors thank M. Dalmas (Malta National Cancer Registry), A. Znaor (Croatian National Cancer Registry), J. Borras (Institut Catala d’Oncologia) for the information that they provided. Some of the data used in this paper were taken from the EUROCIM database of the European Network of Cancer Registries.75 We thank the individual cancer registries for making their data publicly available; their work on collecting and presenting the data is gratefully acknowledged.
The work on this research was
References (117)
- et al.
Estimates of the cancer incidence and mortality in Europe in 2006
Ann Oncol
(2007) - et al.
EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century
Ann Oncol
(2003) - et al.
Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study
Lancet Oncol
(2007) - et al.
Oesophageal cancer in The Netherlands: Increasing incidence and mortality but improving survival
Eur J Cancer
(2007) - et al.
Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990
Eur J Cancer
(1997) - et al.
Gastric cancer: global pattern of the disease and an overview of environmental risk factors
Best Pract Res Clin Gastroenterol
(2006) - et al.
Influence of surgery on outcomes in gastric cancer
Surg Oncol Clin N Am
(2000) - et al.
Epidemiology, treatment and chemoprevention in colorectal cancer
Ann Oncol
(2003) - et al.
Surgical issues in rectal cancer: a 2004 update
Clin Colorectal Cancer
(2004) - et al.
The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas
Gastroenterology
(2007)
Lung cancer mortality in European women: recent trends and perspectives
Ann Oncol
Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands
Ann Oncol
Breast cancer incidence and mortality trends in 16 European countries
Eur J Cancer
Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004
Ann Oncol
Trends in cervical cancer survival in Europe, 1983–1994: a population-based study
Gynecol Oncol
Ten-year survival and risk of relapse for testicular cancer: a EUROCARE high resolution study
Eur J Cancer
Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe
Eur J Cancer
Trends in population-based cancer survival in Germany: to what extent does progress reach older patients?
Ann Oncol
European Code Against Cancer and scientific justification: third version (2003)
Ann Oncol
Global cancer statistics, 2002
CA Cancer J Clin
Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data
Lancet Oncol
Are increasing 5-year survival rates evidence of success against cancer?
Jama
Should we use incidence, survival or mortality to assess breast cancer trends in European women?
Nat Clin Pract Oncol
EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary
Ann Oncol
Head and neck cancer: past, present and future
Expert Rev Anticancer Ther
Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995
Int J Cancer
Trends in survival for both histologic types of esophageal cancer in Switzerland
Int J Cancer
[Importance of regional surgery networks]
Ned Tijdschr Geneeskd
H pylori and gastric cancer: shifting the global burden
World J Gastroenterol
Cancer incidence and mortality in France over the period 1978–2000
Rev Epidemiol Sante Publique
Explaining gastric cancer survival differences among European countries
Int J Cancer
Overweight as an avoidable cause of cancer in Europe
Int J Cancer
Age-period-cohort modeling of colorectal cancer incidence and mortality in Spain
Cancer Epidemiol Biomarkers Prev
Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC)
Int J Cancer
Colon cancer in France: evidence for improvement in management and survival
Gut
Colorectal cancer survival in the Nordic countries and the United Kingdom: Excess mortality risk analysis of 5 year relative period survival in the period 1999 to 2000
Int J Cancer
Pancreatic cancer mortality in Europe: the leveling of an epidemic
Pancreas
Predictors of pancreatic cancer mortality among a large cohort of United States adults
Cancer Causes Control
Overview of the epidemiology of pancreatic cancer focusing on the JACC Study
J Epidemiol
Lifestyle, occupational, and reproductive factors in relation to pancreatic cancer risk
Pancreas
Epidemiology of pancreatic cancer
Minerva Chir
Human cancer: epidemiology and environmental causes
Combined effect of tobacco and alcohol on laryngeal cancer risk: a case-control study
Cancer Causes Control
Cancer of the larynx/hypopharynx, tobacco and alcohol: IARC international case-control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France)
Int J Cancer
Changing Epidemiology of malignant cutaneous melanoma in Europe 1953–1997: rising trends in incidence and mortality, but recent stabilisations in Western Europe and decreases in Scandinavia
Int J Cancer
Melanoma/skin cancer screening in a Mediterranean country: results of the Euromelanoma Screening Day Campaign in Greece
J Eur Acad Dermatol Venereol
A statistical view of the life of women and men in the EU25
Eurostat News Release
Cited by (636)
Unlocking the synthetic approaches and clinical application of approved small-molecule drugs for gastrointestinal cancer treatment: A comprehensive exploration
2023, European Journal of Medicinal ChemistryEmerging trends in photodynamic therapy for head and neck cancer: A 10-year bibliometric analysis based on CiteSpace
2022, Photodiagnosis and Photodynamic TherapyTumorigenic activity of alternative per- and polyfluoroalkyl substances (PFAS): Mechanistic in vitro studies
2022, Science of the Total Environment
- 1
Both authors contributed equally to the manuscript.